A secondary advantage of CD137 enrichment directly from tumor digest is that it facilitates omitting the pre-REP culture and therefore enables the manufacturing of a clinically relevant TIL product within only 16 days, making it one of the shortest processes for TIL manufacturing currently described. This evidence concerns the gene TNFRSF9 and neoplasm.